AstraZeneca Quote - AZN

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

54.17

Bid

Offer

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

83.972B

Previous Close

54.17

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

1,550,163,000

Dividend Yield

PE Ratio

27.86

Earnings Per Share (EPS)

3.84

Revenue

45.81B

Net Profit

5.96B

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from intern... A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its revenue. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Headquarters

Cambridge, Gbr

Founded

Targeting Cancer's Achilles Heel: AI-Driven DDR Therapies Offer Hope

Cancer, a complex disease characterized by uncontrolled cell growth and proliferation, is often rooted in defects within DNA repair mechanisms. Normally, cells possess intricate To read the full...

Biotech Shares Soar After AstraZeneca Stake & Research Collaboration

A Paris-based healthcare company saw an insanely bullish session on Wednesday after it was announced that AstraZeneca

EVUSHELD™ significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations

Pre-exposure prophylaxis (prevention) trial reduced risk of symptomatic COVID-19, with no severe disease or COVID-19-related deaths in EVUSHELD group Data published in the New England Journal of...

ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks

Analysis of Phase III CHAMPION-MG trial open-label extension adds to growing body of safety and efficacy data for ULTOMIRIS in generalized myasthenia gravis Patients who transitioned from...

AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees

Partnership contributes to the AZ Forest global initiative to plant and maintain 50 million trees worldwide by the end of 2025 AstraZeneca has partnered with The National Fish and Wildlife...

EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies

First in vivo data from Washington University show EVUSHELD reduces viral burden of all tested Omicron subvariants in the lungs New preclinical authentic ‘live’ virus data from Washington...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast Cancer

First HER2-low metastatic breast cancer Phase III results for AstraZeneca and Daiichi Sankyo’s ENHERTU offer potential to redefine how the disease is classified and treated Positive high-level...

LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer

Combination was well tolerated and allowed patients to maintain their quality of life vs. patients treated with abiraterone alone PROpel Phase III trial results show clinically meaningful...

Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis

Eplontersen has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of transthyretin-mediated amyloidosis, a systemic, progressive and...

IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years

A single priming dose of tremelimumab plus IMFINZI every four weeks reduced risk of death by 22% in HIMALAYA Phase III trial Combination also showed no increase in severe liver toxicity and...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AAMAA Mission Acquisition Corp	US$ 10.075 (0.00%)	0
AACT.UAres Acquisition Corporation II	US$ 10.9874 (0.00%)	0
AACTAres Acquisition Corporation II	US$ 10.93 (0.00%)	0
AAAlcoa Corporation	US$ 41.99 (0.00%)	0
AAgilent Technologies	US$ 144.00 (0.00%)	0
AAMAA Mission Acquisition Corp	US$ 10.075 (0.00%)	0
AACT.UAres Acquisition Corporation II	US$ 10.9874 (0.00%)	0
AACTAres Acquisition Corporation II	US$ 10.93 (0.00%)	0
AAAlcoa Corporation	US$ 41.99 (0.00%)	0
AAgilent Technologies	US$ 144.00 (0.00%)	0
AAMAA Mission Acquisition Corp	US$ 10.075 (0.00%)	0
AACT.UAres Acquisition Corporation II	US$ 10.9874 (0.00%)	0
AACTAres Acquisition Corporation II	US$ 10.93 (0.00%)	0
AAAlcoa Corporation	US$ 41.99 (0.00%)	0
AAgilent Technologies	US$ 144.00 (0.00%)	0